Article summary
The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on 16 April 2025 detailing requirements for risk minimisation measures for medicines. The guidance outlines how Marketing Authorisation Holders must implement both routine and additional risk minimisation measures, including patient guidance, controlled access programmes, and pregnancy prevention programmes. It explains MHRA's decision-making process for requiring additional measures and specifies that all materials must be MHRA-approved before distribution. The guidance aims to ensure safe medicine use through clear protocols for healthcare professionals and patients.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial